Sonoma Pharmaceuticals, Inc.
SNOA
$1.10
-$0.03-2.66%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 27.87% | -22.39% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 27.87% | -22.39% | |||
| Cost of Revenue | 25.23% | -22.53% | |||
| Gross Profit | 32.18% | -22.17% | |||
| SG&A Expenses | 12.20% | -5.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.60% | -15.38% | |||
| Operating Income | 48.23% | -101.19% | |||
| Income Before Tax | 47.63% | -29.82% | |||
| Income Tax Expenses | 164.62% | 34.01% | |||
| Earnings from Continuing Operations | 29.06% | -53.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 29.06% | -53.37% | |||
| EBIT | 48.23% | -101.19% | |||
| EBITDA | 50.62% | -113.95% | |||
| EPS Basic | 29.95% | -47.38% | |||
| Normalized Basic EPS | 48.30% | -24.71% | |||
| EPS Diluted | 29.95% | -47.38% | |||
| Normalized Diluted EPS | 48.30% | -24.71% | |||
| Average Basic Shares Outstanding | 1.28% | 4.07% | |||
| Average Diluted Shares Outstanding | 1.28% | 4.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||